NIce18 Jun 2022 11:16
I have read some utter rubbish over the last few days. From both sides of the de-ramp/ramp divide.
lets sort a few things out
The Nice assessment pathway which the GDR test is now going through is not a regulatory approval, the test has all the approvals needed to be sold to the NHS and in Europe. The Nice assessment is to see weather the test is going to enter best practice treatment guidance. To do this it has to satisfy some financial and clinical need criteria, so if it can be shown it saves money or changes lives considerably then it becomes best practice. This will mean should be used in every NHS hospital (that is the prize). It does not mean that until it is assessed no hospitals will take it up till then or that the large number of private hospitals will not take it up or that other European hospitals will not take it up. So the idea that there is no possibility of sales till it is granted is utterly idiotic. The fact that nice are assessing the GDR test is a huge step forward in the commercialization of the company.
The recent spike in Covid cases is a warning to us that winter could again be tricky and for companies like GDR, offer an opportunity it here or abroad. The Covid virus is mutating and as recent reports have stated herd immunity does not seam to work as the virus is now significantly different from the original virus. My best guess is that our prime minister will need a hide something behind a big announcement at some point and before we know it face masks and working from home are back, testing will be the way out of this. Covid will not vanish over night.
Our issue here is with the SP, the company is stuck awkwardly between R & D phase and commercialization phase where share holders expectations change from investing on potential to investing on sales. It has to be said that this is the awkward position at which many great ideas fall short and companies fail, it is my strong belief that GDR has the product quality to commercialize successfully, there can be few here who don't think that the hearing loss test would not be a valuable addition to any health service.
We have, since Covid a new type of investor, on the whole ones who know little or nothing about the sector they have invested in, time scales in particular seam prolonged and periods of none communication weaken peoples resolve. understandable but frustrating as small rises in share price are continually eroded. People scream for RNS's daily this just isn't going to happen, we will hear stuff when it occurs. What each of us have to judge is where this will end up and at what point do you either give up and accept a loss or hold for the gold at the end of the rainbow, or to play the swing game and trade the small peaks and troughs. Each and everyone of us on here posts with an agenda even if that agenda is purely to inform. Take everything with a pinch of salt (even what I write)
Sign In
Follow the stocks
